Tevogen Bio Holdings Inc. (TVGN)

Tevogen Bio Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021
Selling, General & Admin	4.44	7.95	1.66
Research & Development	4.4	5.77	2.96
Operating Expenses	8.84	13.72	4.62
Operating Income	-8.84	-13.72	-4.62
Interest Expense / Income	1.21	0.93	0.6
Other Expense / Income	50.43	7.38	10.38
Pretax Income	-60.48	-22.04	-15.6
Net Income	-60.48	-22.04	-15.6
Shares Outstanding (Basic)	25	25	25
Shares Outstanding (Diluted)	25	25	25
Shares Change	-1.99%	0.69%	-
EPS (Basic)	-2.44	-0.87	-0.62
EPS (Diluted)	-2.44	-0.87	-0.62
Free Cash Flow	-8.3	-9.13	-5.38
Free Cash Flow Per Share	-0.34	-0.36	-0.21
EBITDA	-58.89	-20.88	-14.99
Depreciation & Amortization	0.38	0.23	0.01
EBIT	-59.27	-21.11	-15

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).